AWARDDEFINITIVE CONTRACTSmall business
Definitive contract 75N93019C00017METACLIPSE THERAPEUTICS CORP
Overview
Award facts
- Net obligations
- $4.15M
- $4,148,210of $4.15M potential value
- Outlays (paid to date)
- $2.65M
- $2.65M paid of $4.15M obligated$2,652,004
- Period of performance
- Aug 16, 2019 to Dec 31, 2022
- Ended
- Modifications
- 8
- Latest action Aug 25, 2022
- Contract type
- Definitive contract
- PIID 75N93019C00017
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
DEVELOPMENT OF MEMBRANE ANCHORED CYTOKINES AS NOVEL VACCINE ADJUVANTS FOR THE ELDERLY.
Dates and value
- Award date
- Signed on Aug 13, 2019
- Potential end of performance
- Dec 30, 2022
- Current value
- $4,148,210Base and exercised options
- Potential value (if all options are exercised)
- $4,148,210
Obligations by fiscal year of action
- FY2020: $2,199,976
- FY2019: $1,948,234
Total across 2 fiscal years: $4,148,210
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Aug 25, 2022. View on USAspending · Recipient on SAM.gov
Recipient
LocationATLANTA, GA
UEIMU6JZBDZR8X1
CAGE code6BYQ1
Business sizeSmall businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt
Parent companyMETACLIPSE THERAPEUTICS CORP
Business types and certifications
Self-certified small disadvantaged businessFor-profit organizationCorporation (not tax-exempt)
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded from
- National institute of allergy and infectious diseases (0885)Program activities075-0885Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Atlanta, Dekalb County, Georgia 30340-3907
- Congressional district (place of performance)
- GA-04As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competition after exclusion of sourcesD
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- Small business set aside - totalSBA
- Contract pricing
- Firm fixed priceJ
- Offers received
- 1
Solicitation and notices
- Solicitation ID
- PHS20171(as reported)
- Solicitation date
- Jan 19, 2018
Contract details
- Subcontracting plan
- Plan not requiredB
- Major program
- Development of membrane anchored cytokines as novel vaccine adjuvants for the elderly
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- No
- Service Contract Act labor standards
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Aug 13, 2019Base obligation at award: $1,948,234
- Latest action
- Aug 25, 2022 — Other administrative actionModification P00007; administrative: no change in scope or value
- Latest substantive action
- Jun 4, 2020 — Supplemental agreement (within scope)Modification P00003; obligation change +$2,199,976
- Actions by type
- Base award1
- Other administrative action7
- Supplemental agreement (within scope)1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
- Contingency, humanitarian or peacekeeping operation
- Presidential issued emergency declaration, or a major disaster declarationC
- Walsh-Healey Act (materials and supplies)
- No
- Construction wage rates (Davis-Bacon)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N930
- Transactions recorded under this award key
- 9
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N930
- Treasury accounts
- 075-2019/2019-0885-000
- 075-2020/2024-0885-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- L: Emergency P.L. 116-123
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression
- COVID-19 supplemental obligations
- $2,199,976
- COVID-19 supplemental outlays
- $2,199,976